Kolon Biotech to Participate in BIX 2026, Showcase Cell and Gene Therapy CDMO Capabilities
End-to-end services from clinical trials to commercial manufacturing
Seeking collaboration with domestic and international companies
Kolon Biotech is looking to expand its global partnerships by leveraging its contract development and manufacturing organization (CDMO) capabilities for cell and gene therapies.
Kolon Biotech, a subsidiary of Kolon Life Science, announced on October 22 that it will participate in BioPlus-Interphex Korea 2026 (BIX 2026), which will be held at COEX in Seoul from October 28 to 30.
During the event, Kolon Biotech will operate an independent booth in the CMO/CDMO Zone and introduce CDMO services for advanced biopharmaceuticals, including cell therapies, genetically modified cell therapies, stem cell therapies, and exosome therapies. It also plans to hold business meetings with domestic and international biotech companies to explore new partnerships and collaboration opportunities.
Kolon Biotech is a cell and gene therapy CDMO specialist established in 2020 after Kolon Life Science spun off its biomanufacturing division. With its Good Manufacturing Practice (GMP) production facility in Chungju, the company can manufacture products ranging from clinical trial materials to commercial products.
The company provides services covering the entire drug development process, from process development and quality testing to GMP manufacturing, regulatory support, storage, and transportation. Its Chungju Bio Plant 1 handles clinical trial materials and initial commercial supply, while Bio Plant 2 is responsible for large-scale commercial supply.
To ensure stable, large-scale cell production, the company is also focused on expanding the use of automation systems and closed processes in its two-dimensional (2D) cell culture processes. It plans to boost productivity and strengthen its cost competitiveness in manufacturing.
Hot Picks Today
"Please Pay Me at Least 3 Million Won a Month": More Than Half of Young People Today Prioritize "Working Conditions" Over Company Size
- Selling Like Crazy Every Year... 30-Year-Old Hetbahn Takes on a New Challenge: Tastes Better Than "Mom's Home Cooking" [On-Site Report]
- I Thought Only 'Old Guys' Ate It... Young People Are Hooked on This 'Unusual Food' at Risk of Disappearing? [Delicious Stories]
- "Hey, Lady, Teach Your Kids to Behave!" ... 300,000 Won in Cash and a Bodily Injury Claim Demanded Over Child's Door Ding
- Beachgoer Finds 'Plastic' That Turns Out to Be Perfume Ingredient Worth More Than Twice as Much as Gold
A Kolon Biotech official said, "At BIX 2026, we will showcase our CDMO capabilities and identify new collaboration opportunities. As a specialized and flexible CDMO partner that reliably supports clients from the development of new drug candidates through commercial production, we will continue to strengthen our competitiveness."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
